Radcliffe Capital Management, L.P. - IBERE PHARMACEUTICALS ownership

IBERE PHARMACEUTICALS's ticker is IBER and the CUSIP is G46843101. A total of 49 filers reported holding IBERE PHARMACEUTICALS in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Radcliffe Capital Management, L.P. ownership history of IBERE PHARMACEUTICALS
ValueSharesWeighting
Q4 2022$3,300,944
+1.8%
327,1500.0%0.10%
+33.3%
Q3 2022$3,242,000
+10.2%
327,150
+9.0%
0.08%
+14.7%
Q2 2022$2,943,0000.0%300,0000.0%0.07%
+1.5%
Q1 2022$2,943,000
+1.1%
300,0000.0%0.07%
-11.8%
Q4 2021$2,910,000
+0.1%
300,0000.0%0.08%
-10.6%
Q3 2021$2,907,000
+0.2%
300,0000.0%0.08%
-6.6%
Q2 2021$2,901,000300,0000.09%
Other shareholders
IBERE PHARMACEUTICALS shareholders Q1 2022
NameSharesValueWeighting ↓
Integrity Capital Management (HK) Ltd 46,717$458,0002.36%
Lynwood Capital Management Inc. 51,400$504,0000.54%
TEGEAN CAPITAL MANAGEMENT, LLC 91,422$896,0000.48%
KRYGER CAPITAL Ltd 422,029$4,140,0000.24%
BASSO CAPITAL MANAGEMENT, L.P. 170,114$1,669,0000.16%
SPRING CREEK CAPITAL LLC 400,000$3,924,0000.16%
Vestcor Inc 400,000$3,924,0000.14%
Castle Creek Arbitrage, LLC 253,446$2,483,0000.12%
ROBINSON CAPITAL MANAGEMENT, LLC 17,881$175,0000.12%
Knott David M Jr 36,000$353,0000.11%
View complete list of IBERE PHARMACEUTICALS shareholders